More new substances recommended for approval in first half, says EMA
This article was originally published in SRA
The number of medicines recommended for approval by the European Medicines Agency in the first half of 2013 rose substantially in the first half of this year compared with the 2012 period1. There was a notable increase in the tally of new active substances, of which four received a positive recommendation under special regulatory procedures for speeding up access to innovative medicines.
You may also be interested in...
The pharmaceutical industry and other stakeholders have taken part in the launch event for a new initiative intended to tackle issues that have been amplified by the COVID-19 pandemic, such as supply chain resilience and medicine shortages. The project has drawn a mixed response from industry bodies.
The MHRA is losing no time in getting its much heralded “new era” of medicines regulation up and running.
Coronavirus Notebook: EMA Issues Guidance On Development Of Variant Vaccines, EU Leaders Urge Production Ramp-Up
A batch of AstraZeneca/Oxford University coronavirus vaccines has arrived in Ghana, the first country in the world to receive vaccines via the COVAX Facility.